Point72 Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Point72 Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-340,000	Closed	-$15.8M	–	4224
2025 Q3	$15.8M	Sell	340,000 -278,142	-45%	-$10.2M	0.03%	634
2025 Q2	$18.1M	Sell	618,142 -234,102	-27%	-$6.37M	0.04%	538
2025 Q1	$21.9M	Buy	852,244 +68,323	+9%	+$1.68M	0.05%	426
2024 Q4	$22.6M	Sell	783,921 -81,021	-9%	-$2.47M	0.05%	413
2024 Q3	$20.5M	Hold	864,942	–	–	0.05%	414
2024 Q2	$15M	Hold	864,942	–	–	0.04%	480
2024 Q1	$19.3M	Buy	+864,942	New	+$18M	0.05%	462
2021 Q4	–	Sell	-714	Closed	-$82K	–	1339
2021 Q3	$82K	Sell	714 -715	-50%	-$106K	﹤0.01%	985
2021 Q2	$307K	Buy	+1,429	New	+$249K	﹤0.01%	891

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Point72 Asset Management's LENZ Position: Q4 2025 in Review

Point72 Asset Management sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 340,000 shares — an estimated $15.8M sold.

Point72 Asset Management first reported a position in LENZ in Q2 2021 and held it in 9 quarters. The position peaked at $22.6M in Q4 2024. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

Point72 Asset Management reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
Point72 Asset Management sold 340,000 LENZ Therapeutics shares in Q4 2025, an estimated $15.8M.
Point72 Asset Management first reported a position in LENZ Therapeutics in Q2 2021 and held it in 9 quarters.
Point72 Asset Management's LENZ Therapeutics position peaked at $22.6M in Q4 2024.
160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.